Skip to Content

A Potential New Standard of Care for Transplant-Eligible Patients with Multiple Myeloma

Pieter Sonneveld discussed in this MEDtalk the PERSEUS trial presented at ASH 2023. The study involved 700 patients across 13 countries and showed promising results in progression-free survival, higher complete response rates, and substantial MRD negativity for transplant-eligible patients with Multiple Myeloma.

Pieter Sonneveld

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top